Avalo Therapeutics (AVTX) Change in Account Payables (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Change in Account Payables data on file, last reported at $219000.0 in Q1 2026.

• Quarterly Change in Account Payables fell 44.97% year-over-year to $219000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$325000.0 (down 38.3% YoY) and the FY2025 annual result came in at -$146000.0, up 10.43% from the prior year.
• Change in Account Payables grew to $219000.0 in Q1 2026, from -$337000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.7 million in Q1 2023 to a low of -$4.8 million in Q2 2023.
• A 5-year average of -$177235.3 and a median of $37000.0 in 2023 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 3027.03% in 2024, down 346.78% in 2024.
• Tracing AVTX's Change in Account Payables over 5 years: stood at $1.4 million in 2022, then plunged by 123.83% to -$342000.0 in 2023, then tumbled by 346.78% to -$1.5 million in 2024, then soared by 77.95% to -$337000.0 in 2025, then soared by 164.99% to $219000.0 in 2026.
• The last three Change in Account Payables figures came in at $219000.0 (Q1 2026), -$337000.0 (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.